Project Grant R50CA288324
Award Date
9/19/24
Completion Date
8/31/29
Dollars Obligated
$172K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
This $437,432 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at developing strategies to eradicate leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) patients who have relapsed after initial treatment with venetoclax and azacitidine. The key goals of the project are to: 1) characterize and target venetoclax/azacitidine-resistant LICs, 2) evaluate the use of lower-dose mitoxantrone in combination...
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, will support a clinical trial and correlative studies focused on improving CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The award, totaling $289,458, will fund the following key products and services over the project period from Sep 1, 2024 to Aug 31, 2029: Conduct a Phase I clinical trial (MEMCAR19; NCT04881240) evaluating an...
This $178,909 Project Grant awarded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) aims to accelerate the incorporation of immunotherapy and CD30-targeted cellular therapy into the treatment of Hodgkin lymphoma in children, adolescents, and young adults (AYAs). The award supports the principal investigator, Dr. Castellino, in her role as the Scientific Chair of the Hodgkin Lymphoma Committee in the Children's Oncology Group. Key...
This $101,948 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize germline variants and perform functional validation of variants in a zebrafish model of high-risk pediatric acute myeloid leukemia (AML). The ultimate goal is to determine if predisposition risk factors like germline mutations and viral infections can be mitigated through screening or prophylaxis. The award, effective September 1,...
The National Cancer Institute (NCI) awarded a 5-year, $481,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Colorado-Denver, effective January 20, 2025. The grant supports research aimed at inhibiting free fatty acid transport to improve chimeric antigen receptor T-cell (CAR-T) therapy for relapsed B-cell acute lymphoblastic leukemia (B-ALL), particularly in cases with TP53 mutations. The research leverages genome-wide CRISPR/Cas9 screening to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $441,178 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at overcoming therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. The key objectives are to: Investigate the cellular and developmental dependency of NUP98-NSD1-mediated leukemic initiation across different hematopoietic stem cell populations. Characterize the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $931,841 to The Leland Stanford Junior University to develop next-generation immunotherapies for pediatric cancers. The funding will support research to overcome the suppressive tumor microenvironment in pediatric solid tumors, optimize multi-specific CAR T cells, and explore in vivo gene delivery approaches to engineer immune populations without ex vivo manufacturing. This work aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $768,713 project grant to St. Jude Children's Research Hospital Inc. The grant, effective August 1, 2025 through July 31, 2030, will support research aimed at understanding how the histone acetyltransferase proteins EP300 and CBP control cell state plasticity and chemotherapy resistance in pediatric neuroblastoma. The project will use novel cell state reporter systems and...